Last update April 27, 2024

バルサルタン

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Valsartan is an angiotensin II receptor antagonist (ARA) with actions similar to those of losartan. It is indicated in the treatment of hypertension, left ventricular dysfunction after myocardial infarction and in heart failure. Oral administration once or twice daily. 

At the time of the last update, we found no published data on its excretion in breast milk. 

Its high binding to plasma proteins makes it unlikely to pass into milk, and its low oral bioavailability means that passage into plasma from ingested breast milk is difficult in infants, except in premature infants and the immediate neonatal period, in which there may be greater intestinal permeability. 

Until more data on this drug are known, safer known alternatives are preferable (Malachias 2016, Rowe 2013), especially in the neonatal period and in case of prematurity.

Alternatives

  • Candesartan Cilexetil ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Captopril ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Enalapril ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Quinapril Hydrochloride ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

バルサルタン is Valsartan in Japanese.

Is written in other languages:

Tradenames

Main tradenames from several countries containing バルサルタン in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 23 - 39 %
Molecular weight 436 daltons
Protein Binding 97 %
VD 0.24 l/Kg
pKa 8.15 -
Tmax 2 - 4 hours
6 - 9 hours

References

  1. Malachias MV, Figueiredo CE, Sass N, Antonello IC, Torloni MR, Bortolotto MRF L. 7th Brazilian Guideline of Arterial Hypertension: Chapter 9 - Arterial Hypertension in pregnancy Arq Bras Cardiol. 2016 Abstract Full text (link to original source)
  2. Rowe H, Baker T, Hale TW. Maternal medication, drug use, and breastfeeding. Pediatr Clin North Am. 2013 Feb;60(1):275-94. Abstract
  3. AEMPS. Valsartán. Ficha técnica. 2009 Full text (in our servers)
  4. MHRA. Valsartan. Drug Summary. 2009 Full text (in our servers)
  5. Tamargo j, Caballero R, Gómez R, Núñez L, Vaquero M y Delpón E. Características farmacológicas de los ARA-II. ¿Son todos iguales?. Rev Esp Cardiol Supl. 2006;6:10C-24C. 2006 Full text (in our servers)

Total visits

932

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM